Clinical trials: Nivolumab
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab
- Trial name
- NIVO-ALCL (NCT03703050)
- Testing
- Nivolumab cohort 1, Nivolumab cohort 2
- Where
- 13 sites in Denmark, France and 1 more
- Volunteers
- 45 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT…
- Trial name
- NCT04396860
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab
- Where
- 285 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Skin Cancer
Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
The purpose of this study is to evaluate the efficacy of immunotherapy in the first-line treatment of metastatic melanoma in Slovenia and to investigate the association between PD-L1 expression and treatment response.
- Trial name
- MAK (NCT07422779)
- Testing
- Pembrolizumab, Nivolumab, Ipilimumab
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- Institute of Oncology Ljubljana
Hodgkin Lymphoma
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL.
- Trial name
- NCT07234487
- Testing
- Nivo-AVD, BEACOPP-like
- Where
- 3 sites in Russia
- Volunteers
- 178 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Clear Cell Renal Cell Carcinoma
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
- Trial name
- NCT03680521
- Testing
- Sitravatinib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mirati Therapeutics Inc.
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
This phase I trial tests the safety, side effects, and best dose of camu camu when used in combination with nivolumab and ipilimumab in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT06049576
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Rectal Cancer
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer
This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab and nivolumab in rectal cancer.
- Trial name
- CHINOREC (NCT04124601)
- Testing
- Chemoradiotherapy, Ipilimumab, Nivolumab
- Where
- 5 sites in Austria
- Volunteers
- 80 people
- Sponsor
- Johannes Laengle, MD, PhD
Kidney Cancer, Renal Cell Carcinoma Metastatic
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
BACKGROUND: For synchronous metastatic renal cell carcinoma (RCC), surgical resection of the primary tumor in the presence of distant metastases has been the standard of therapy for select patients followed by systemic therapy.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma Metastatic, Synchronous Neoplasm
- Trial name
- NORDIC-SUN (NCT03977571)
- Testing
- Cytoreductive nephrectomy, Tissue sampling
- Where
- 11 sites in Denmark, Finland and 2 more
- Volunteers
- 400 people
- Sponsor
- Niels Fristrup
Various Advanced Cancer
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus…
- Trial name
- CheckMate 648 (NCT03143153)
- Testing
- Nivolumab, Ipilimumab, Cisplatin
- Where
- 190 sites in United States, Argentina and 25 more
- Volunteers
- 970 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancies
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, is safe and tolerable in the treatment of advanced malignancies.
- Trial name
- NCT03158272
- Testing
- Cabiralizumab, Nivolumab
- Where
- 4 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Cancer
A Study of BND-35 in Participants With Advanced Solid Tumors
This is an open-label, multicenter, dose escalation and dose optimization study designed to evaluate safety, tolerability and preliminary anti-tumor activity of BND-35 administered alone and in combination with nivolumab or with…
- Trial name
- NCT06274437
- Testing
- BND-35, Nivolumab, Cetuximab
- Where
- 5 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Biond Biologics
Soft Tissue Sarcoma Adult
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
- Trial name
- NCT03056599
- Testing
- Multiple drug microinjection, CIVO device
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Presage Biosciences
Gastric Cancer
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy…
- Trial name
- NCT06256328
- Testing
- ONO-4578, Oxaliplatin, Capecitabine
- Where
- 63 sites in Japan, South Korea and 1 more
- Volunteers
- 226 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Breast Cancer
Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
This is a single center non-blinded randomized non-comparative phase II trial. The first stage of the trial consists of five arms ( with induction treatment followed by nivolumab, 1 with no induction treatment before nivolumab).
- Trial name
- TONIC (NCT02499367)
- Testing
- Nivolumab, Radiation therapy, Low dose doxorubicin
- Where
- Netherlands
- Volunteers
- 84 people
- Sponsor
- The Netherlands Cancer Institute
Non-small Cell Lung Cancer Stage I
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer
Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy…
- Trial name
- NCT04271384
- Testing
- nivolumab
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Hospital Israelita Albert Einstein
Triple Negative Breast Cancer
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Prior to Amendment #7: The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating…
- Trial name
- NCT04331067
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
This phase II trial studies how well nivolumab works in eliminating any remaining cancer cells and preventing cancer from returning in patients with acute myeloid leukemia that had a decrease in or disappearance of signs and…
- Trial name
- NCT02275533
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation
- Where
- 46 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
This phase I trial studies how well CBM588 works when given together with nivolumab and ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other places in the body (advanced).
- Conditions
- Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT03829111
- Testing
- Clostridium butyricum CBM 588 Probiotic Strain, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center